Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629769 | 0.86 | METAP2 (0.53) | METAP2BACE1CCR1RAB9ACCR5 | |
| SCHEMBL30657716 | 0.77 | BACE1 (0.63) | METAP2BACE1CCR1RAB9ACCR5 | |
| SCHEMBL339928 | 0.77 | BACE1 (0.63) | METAP2BACE1CCR1RAB9ACCR5 | |
| SCHEMBL2115749 | 0.77 | CCR1 (0.64) | METAP2CCR1RAB9ACCR5KDM4E | |
| SCHEMBL806441 | 0.77 | CCR1 (0.64) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL13738421 | 0.76 | CCR1 (0.61) | METAP2CCR1RAB9ACCR5KDM4E | |
| Neocuproine SCHEMBL29639703 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5KDM4E | |
| Neocuproine SCHEMBL29367091 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5KDM4E | |
| Neocuproine SCHEMBL11672280 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5KDM4E | |
| Neocuproine SCHEMBL124563 | 0.75 | CCR1 (1.00) | METAP2CCR1RAB9ACCR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113666964-B | Preparation and application of thioiminoquinoline metal compound | 青岛科技大学 | 2023-03-14 | — | — | CN | claimed |
| CN-113754583-A | 2- ([2, 2' -biquinolyl ] -3-ether) -1-ethanol and derivative and synthetic method thereof | 湖南工程学院 | 2021-12-07 | — | — | CN | claimed |
| CN-113666964-A | Preparation and application of thioiminoquinoline metal compound | 青岛科技大学 | 2021-11-19 | — | — | CN | claimed |
| CN-101602723-B | Preparation method of 2-methyl-8-aminoquinoline | UNIV HUNAN | 2011-06-08 | — | — | CN | claimed |
| CN-101602723-A | The preparation method of 2-methyl-8-quinolylamine | UNIV HUNAN (CN) | 2009-12-16 | — | — | CN | claimed |
| EP-4701782-A1 | CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS | Chevron Phillips Chemical Company LP (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4701783-A1 | PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES | Chevron Phillips Chemical Company LP (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12281065-B2 | Iron catalyzed highly enantioselective cis-dihydroxylation of quinones | VERSITECH LIMITED (CN) | 2025-04-22 | — | — | US | disclosed |
| US-20240400473-A1 | CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2024-12-05 | — | — | US | disclosed |
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | UNIV RUTGERS (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024226492-A1 | PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024226497-A1 | CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2024-10-31 | — | — | WO | disclosed |
| US-6437161-B1 | OLEFIN POLYMERIZATION CATALYSTS; SUBSTITUENT ON THE CYCLOPENTADIENYL RING CARRIES A DONOR FUNCTION WHICH IS BONDED RIGIDLY, NOT EXCLUSIVELY VIA SP3-HYBRIDIZED CARBON OR SILICON ATOMS, | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| EP-1212333-A1 | MONOCYCLOPENTADIENYL COMPLEXES OF CHROMIUM, MOLYBDENUM OR TUNGSTEN WITH A DONOR BRIDGE | Basell Polyolefine GmbH (DE) | 2002-06-12 | — | — | EP | disclosed |
| EP-1196410-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001012641-A1 | MONOCYCLOPENTADIENYL COMPLEXES OF CHROMIUM, MOLYBDENUM OR TUNGSTEN WITH A DONOR BRIDGE | BASELL POLYOLEFINE GMBH (DE) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001000615-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| WO-1999041239-A1 | B CELL INHIBITORS | NOVARTIS AG (CH) | 1999-08-19 | — | — | WO | disclosed |
| US-4530931-A | 8-Quinoline carbanilates for the inhibition of lipolysis | USV PHARMACEUTICAL CORP. (US) | 1985-07-23 | — | — | US | disclosed |
| EP-0014929-A1 | Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids | Roche Diagnostics GmbH (DE) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | NDC1, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | METAP2 4453/4885BACE1 4280/4885CCR1 1801/4885 |
| US-12281065-B2 | Iron catalyzed highly enantioselective cis-dihydroxylation of quinones | NFE2L2, DUOX1, DUOX2 | METAP2 2388/4885BACE1 608/4885CCR1 4491/4885 |
| US-20240400473-A1 | CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS | AP1M1, AP2M1, OXER1 | METAP2 4076/4885BACE1 1039/4885CCR1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.